CNS Therapeutics Market
完整報告名稱與涵蓋範圍
CNS Therapeutics Market Size, Share & Trends Analysis Report, By Therapeutic Area (Neurodegenerative Disorders, Psychiatric Disorders, Epilepsy and Rare Neurological Diseases, Migraine and Pain, Multiple Sclerosis and Neuroimmunology), By Drug Modality (Small Molecules, Monoclonal Antibodies, Gene, Cell and Oligonucleotide Therapies, Psychedelic and Rapid-Acting Agents), By Route of Administration (Oral, Injectable, Intranasal and Other Routes), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The CNS therapeutics market comprises prescription medicines for disorders of the central nervous system across neurology and psychiatry, including neurodegenerative diseases, psychiatric disorders, epilepsy and rare neurological conditions, migraine and neuropathic pain, and multiple sclerosis and neuroimmunology, covering small molecules, antibodies, genetic medicines and rapid-acting agents. Anesthetics, over-the-counter products and medical devices for neuromodulation are excluded.
After years of attrition, the field is being revitalised by disease-modifying antibodies for Alzheimer's disease, a muscarinic agonist that created the first new schizophrenia mechanism in decades, rapid-acting antidepressants, CGRP-based migraine therapies and oligonucleotide and gene therapies for rare neurological diseases. Blood-based biomarkers and digital assessment tools are improving diagnosis and trial design, while psychedelic-assisted therapies and precision approaches in epilepsy and neurodevelopmental disorders extend the pipeline. Commercial performance depends on infusion and monitoring infrastructure, payer acceptance of high-cost therapies and the loss of exclusivity for several large psychiatry and multiple sclerosis brands.
North America, Europe and Japan generate most revenue, with China expanding access to novel neurology agents. The competitive landscape includes diversified neuroscience franchises, specialist psychiatry and epilepsy companies and genetic medicine developers.
The InsightAce study supplies US$ forecasts for all therapeutic area, drug modality, route of administration and distribution channel and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CNS Therapeutics Market Snapshot
Chapter 4. Global CNS Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Therapeutic Area Estimates & Trend Analysis
5.1. Therapeutic Area & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
5.2.1. Neurodegenerative Disorders
5.2.2. Psychiatric Disorders
5.2.3. Epilepsy and Rare Neurological Diseases
5.2.4. Migraine and Pain
5.2.5. Multiple Sclerosis and Neuroimmunology
Chapter 6. Market Segmentation 2: By Drug Modality Estimates & Trend Analysis
6.1. Drug Modality & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Modality:
6.2.1. Small Molecules
6.2.2. Monoclonal Antibodies
6.2.3. Gene, Cell and Oligonucleotide Therapies
6.2.4. Psychedelic and Rapid-Acting Agents
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Oral
7.2.2. Injectable
7.2.3. Intranasal and Other Routes
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Specialty Pharmacies
Chapter 9. CNS Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Eli Lilly and Company
11.2. Biogen Inc.
11.3. Eisai Co., Ltd.
11.4. Johnson & Johnson
11.5. AbbVie Inc.
11.6. Bristol Myers Squibb
11.7. Novartis AG
11.8. Roche Holding AG
11.9. Otsuka Pharmaceutical Co., Ltd.
11.10. Lundbeck A/S
11.11. Teva Pharmaceutical Industries Ltd.
11.12. UCB S.A.
11.13. Jazz Pharmaceuticals plc
11.14. Ionis Pharmaceuticals, Inc.
11.15. Axsome Therapeutics, Inc.
圖表清單 List of Tables & Figures
Table 1. Global CNS Therapeutics Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 1. Global CNS Therapeutics Market Snapshot, 2026 & 2035
Table 2. Global CNS Therapeutics Revenue Forecast by Drug Modality, 2026-2035 (US$ Mn)
Figure 2. Global CNS Therapeutics Market Share by Drug Modality, 2026 & 2035
Table 3. Global CNS Therapeutics Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. CNS Pipeline by Therapeutic Area, Modality and Phase, 2026
Table 4. Global CNS Therapeutics Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Disease-Modifying Therapy Adoption Curve in Alzheimer's Disease, 2026-2035
Table 5. North America CNS Therapeutics Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific CNS Therapeutics Growth Opportunity Analysis
Table 6. Europe CNS Therapeutics Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Loss-of-Exclusivity Calendar for Major Psychiatry and Neurology Brands
Table 7. Asia Pacific CNS Therapeutics Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key CNS Therapeutics Market Participants
Table 8. Latin America and Middle East & Africa CNS Therapeutics Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們